Editas Medicine股价分析 - Editas Medicine (EDIT) 过去四周股价上涨0.7%，收盘价为$8.15，根据华尔街分析师的短期价格目标，平均估值为$14.67，潜在上涨幅度为80%[1] - 分析师对Editas Medicine的短期价格目标范围从$7到$27，标准偏差为$6.69，标准偏差越小，分析师间的一致性越高[2] - 仅仅依靠共识价格目标来做投资决策可能不明智，分析师设置价格目标的能力和公正性一直存在争议[3] - 分析师们普遍认为公司的盈利将优于他们之前的估计，盈利预期修订的积极趋势有助于预测股价上涨[4]

业绩总结 - Editas Medicine是一家专注于CRISPR基因编辑的临床阶段公司[6] - reni-cel项目针对镰状细胞病和β地中海贫血，已展示出早期和强有力的贫血矫正效果[12] - beta地中海贫血患者的胎儿血红蛋白水平达到9克/分升，超过了需要输血的阈值[28] 用户数据 - reni-cel治疗使患者总血红蛋白水平达到正常生理范围，并显著增加胎儿血红蛋白超过40%[12] - reni-cel治疗后患者不再需要输血，且所有患者成功植入中性粒细胞和血小板[13] 未来展望 - 预计今年中和年底将发布两次reni-cel的数据，BLA提交时间预计在2025年下半年[39] 新产品和新技术研发 - reni-cel使用AsCas12a酶进行基因编辑，具有更高的特异性和高效率[15] 市场扩张和并购 - 公司与Azzur扩大合作，增加了reni-cel的制造能力，以支持BLA申请和商业化[42] - 扩大合作将有助于支持BLA和商业化，采用一种非传统的CDMO合作模式，利用Azzur的设施，但由公司的制造人员提供支持[43] 负面信息 - CMS将代表医疗补助计划与镰状细胞病治疗制造商进行谈判，显示对细胞基因疗法的重视[34] 其他新策略和有价值的信息 - FDA批准Casgevy后，RUBY研究的招募和参与度保持强劲势头[30] - 公司正在努力缩短制造时间，特别是在质控释放方面寻找机会，以缩短制造时间线[46]

生物技术行业前景 - 生物技术行业前景光明，受益于新药批准和积极的管道[1] 公司合作与收购 - 大型制药/生物技术公司通过合作和收购来增强产品组合和管道[2] 行业领先公司展望 - Sarepta Therapeutics, Inc. (SRPT), Exelixis, Inc. (EXEL), Immunocore Holdings plc (IMCR), Editas Medicine, Inc. (EDIT)和Puma Biotechnology, Inc. (PBYI)等生物技术公司有望在波动的行业中表现优异[3]

Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Debjit Chattopadhyay Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill. Thank you so much for your time Gilmore. And if we could start ...

Editas Medicine, Inc. (NASDAQ:EDIT) Guggenheim 6th Annual Biotechnology Conference February 7, 2024 9:30 AM ET Company Participants Gilmore O'Neill - President and CEO Conference Call Participants Debjit Chattopadhyay - Guggenheim Debjit Chattopadhyay Good morning. Thank you for joining the Guggenheim Securities Healthcare team at our 6th Annual Conference. I'm Debjit and joining us from Editas Medicine is its President and CEO, Gilmore O'Neill. Thank you so much for your time, Gilmore. And if we could star ...

Zacks评级系统 - Zacks评级系统核心在于跟踪卖方分析师对股票的盈利预期，这对个人投资者非常有用[2] - Zacks Rank股票评级系统利用盈利预期修订的力量，对于投资决策非常有帮助[7] - Zacks Rank股票评级系统自1988年以来表现出色，Zacks Rank 1股票的平均年回报率为+25%[8] - Zacks评级系统保持着'buy'和'sell'评级的平衡，只有前5%的股票获得'Strong Buy'评级，而接下来的15%获得'Buy'评级，所以位于前20%的股票具有优秀的盈利预期修订特性，有望在短期内产生市场超额回报[11] Editas Medicine (EDIT) - Editas Medicine最近被升级为Zacks Rank 2 (Buy)，这是因为其盈利预期上升，这是影响股价的最强力量之一[1] - Editas的盈利前景获得Zacks评级升级，这对其股价有积极影响[4] - Editas的盈利预期上升和评级升级意味着公司基本业务的改善，投资者应该对此表示赞赏并推动股价上涨[6] - Editas预计在2023年度财年结束时每股亏损2.23美元，同比增长30.5%[9] - 过去三个月，分析师一直在提高对Editas的盈利预期，Zacks Consensus Estimate增长了1.9%[10] - Editas被升级为Zacks Rank 2，位于Zacks覆盖股票的前20%，意味着股价可能在短期内上涨[13]

CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced that management will participate in the following upcoming investor conferences to discuss the Company and its programs, including reni-cel: Guggenheim 6th Annual Biotechnology ConferenceFormat: Fireside ChatDate: Wednesday, February 7Time: 9:30 a.m. ETLocation: New York, NY Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Fireside ChatDate: Tues ...

What's the appeal of investing in relatively small and little-known corporations? Though these businesses come with heightened risks, getting in on the ground floor can potentially be lucrative over the long run if they become successful. Just think: What if you had invested in a massively successful biotech giant like Vertex Pharmaceuticals in its early days?Let's look at two relatively small biotechs that, if enough goes right, could deliver outsize returns to those who invest now: Editas Medicine (EDIT - ...

Editas Medicine的股价表现 - Editas Medicine的股价在过去三年中下跌了约88%，尽管最近有关其实验疗法和知识产权的积极消息[1] - Editas的股价可能会因为Ruby研究的进一步结果而大幅上涨，公司预计将在2024年中期和年底再次公布这些结果[6] - Editas目前没有任何产品出售，但由于来自Vertex的付款，公司预计不会在2026年之前用尽现金[10] Editas的疗法和商业化前景 - Editas正在推动其第一个基于CRISPR的疗法走向商业化，其实现商业化的机会似乎比以往任何时候都更好[2] - Editas是唯一拥有许可证允许其使用CRISPR技术编辑人类基因的公司，而且在CRISPR和知识产权方面有很多细节[8] - Vertex Pharmaceuticals向Editas Medicine支付了5000万美元的前期费用，以获得使用reni-cel依赖的基因编辑过程的非独家许可证，这可能会为Editas带来更多的资金[9] Editas的研究和产品进展 - Editas目前没有任何已批准的产品出售，但公司仍在进行其主要候选药物reni-cel的研究，并预计在未来几年内可能会有所改变[4] - CRISPR Therapeutics和Vertex Pharmaceuticals的Casgevy也帮助SCD患者避免了血管阻塞性事件，这可能会影响reni-cel的销售预期[12] - Editas Medicine目前只有一个处于临床阶段的项目，而且至少还需要一年才能向FDA提交申请，因此股价可能过高[14] - 在reni-cel距离商业化更近之前，最好还是远离这支股票[15]

Dima, Tristan, & Stephanie 1 January 2024 Forward Looking Statements This presentation contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words ''anticipate,'' ''believe,'' ''continue,'' ''could,'' ''estimate,'' ''expect,'' ''intend,'' ''may,'' ''plan,'' ''potential,'' ''predict,'' ''project,'' ''target,'' ''should,'' ''would,'' and similar expressions are intended to identify forward-looking statements, although not all forwar ...